On July 29, 2025, Novo Nordisk reported a lowered sales growth outlook for 2025 to 8-14%, down from 13-21%, and operating profit growth expectations to 10-16%, down from 16-24%. This adjustment is due to lower growth expectations for its Wegovy and Ozempic products in the U.S. market.